TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8398824
Drug: Melphalan treatment
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan treatment
Study: 28954640
Drug: beta2-1 fructan
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta2-1 fructan (3x5 g/d for 28 days)
Study: 28954640
Drug: maltodextrin (3x5
Approvals — FDA: no, EMA: no, PMDA: no
Description: maltodextrin (3x5 g/d for 28 days)
Study: 21694627
Drug: Tianeptine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (75 mg)
Study: 16931978
Drug: Endobronchial blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial blocker
Study: 1290169
Drug: Antithrombin III
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin III (ATIII) replacement therapy before the induction of anaesthesia and throughout surgery
Study: 1290169
Drug: No Antithrombin
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Antithrombin III replacement therapy
Study: 30673543
Drug: Levodopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (100 mg three times per day) in combination with carbidopa (25 mg three times per day) for 80 weeks
Study: 30673543
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 40 weeks followed by levodopa in combination with carbidopa for 40 weeks
Study: 30673543
Drug: Levodopa in
Normalized name: levodopa Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa in combination with carbidopa
Study: 29494727
Drug: Ranibizumab and
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab and laser combination therapy
Study: 21415158
Drug: Copeptin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copeptin levels in the highest quartile (>122 pmol/L)
Study: 17550216
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (GLAR; n=74)
Study: 17550216
Drug: NPH/semilente insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH/semilente insulin (NPH; n=68)
Study: 14504683
Drug: Baclofen (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (0, 10, 20 and 30 mg)
Study: 20638380
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine (45 mg)
Study: 20638380
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 mg)
Study: 9071430
Drug: Dronabinol 2.5
Normalized name: dronabinol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol 2.5 mg twice/day (D)
Study: 9071430
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 750 mg/day (M750)
Study: 9071430
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 750 mg/day + dronabinol 2.5 mg twice/day (M750+D)
Study: 9071430
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 250 mg/day + dronabinol 2.5 mg twice/day (M250+D)
Study: 30790061
Drug: Probe drugs
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probe drugs and endogenous substrates
Study: 26836729
Drug: Subcutaneous dupilumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dupilumab (600 mg loading dose followed by 300 mg weekly)
Study: 26836729
Drug: Subcutaneous dupilumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dupilumab
Study: 18592619
Drug: Proactive tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proactive tacrolimus 0.1% ointment applied twice weekly
Study: 18592619
Drug: Vehicle ointment
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ointment applied twice weekly
Study: 9990217
Drug: Pentazocine 0.5
Normalized name: naloxone-pentazocine 0.5 mg-50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 0.5 mg.kg‐1
Study: 2464358
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (not specified)
Study: 26670614
Drug: Pregabalin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75 mg qid to 300 mg bid)
Study: 16417778
Drug: YBK Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: YBK Tablets (40 mg, three times per day)
Study: 16417778
Drug: Leucogen Tablets
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Leucogen Tablets (20 mg, three times per day)
Study: 16417778
Drug: Placebo (Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Vitamin C tablets 100 mg, three times per day)
Study: 12708879
Drug: Perindopril 2mg/Indapamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2mg/Indapamide 0.625 mg
Study: 8767824
Drug: Single-dose fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose fluconazole (150 mg)
Study: 8767824
Drug: 7-day fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day fluconazole treatment (daily 50 mg)
Study: 1616165
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 micrograms) with 40 mL of 1% lidocaine
Study: 1616165
Drug: Epinephrine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (200 micrograms) with 40 mL of 1% lidocaine
Study: 6589042
Drug: Early intensification
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intensification therapy with two doses of asparaginase during induction therapy
Study: 6589042
Drug: Delayed intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed intensification therapy with four doses of asparaginase and cytarabine after remission induction
Study: 6589042
Drug: Late intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late intensification therapy added to maintenance protocol
Study: 27423162
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) self-help workbook
Study: 24326811
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser treatment (980 nm wavelength) after biomechanical preparation in Group A
Study: 15605279
Drug: Blackcurrant anthocyanin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blackcurrant anthocyanin (BCA) 17 mg kg(‐1)
Study: 15605279
Drug: Blackcurrant anthocyanin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blackcurrant anthocyanin (BCA) 7.7 mg kg(‐1)
Study: 10219807
Drug: Chemotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin and 5‐fluorouracil) alternated with radiotherapy (60 Gy/30 fractions)
Study: 3539826
Drug: Oral timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral timolol
Study: 7970548
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol alone
Study: 31154316
Drug: LEGO-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEGO-based therapy with usual care
Study: 26007264
Drug: Isosorbide Mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide Mononitrate (IMN) 40 mg tablet vaginally every 6 hours for a maximum of 4 doses
Study: 26007264
Drug: Misoprostol 50
Normalized name: diclofenac-misoprostol 50 mg-200 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 50 μg tablet vaginally every 6 hours for a maximum of 4 doses
Study: 21443321
Drug: CBT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT plus interpersonal and emotional processing therapy (n = 43)
Study: 25816542
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin A 5,000 IU 3 times/week for four weeks
Study: 22218160
Drug: Increased intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased intake of oily fish (2 portions of salmon per week providing 3.45 g EPA plus DHA) from 20 weeks gestation until delivery
Study: 19949851
Drug: Biofeedback-assisted behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback-assisted behavioral treatment with Internet-based client-therapist contact
Study: 12814227
Drug: System B
Normalized name: ACCESS PORT SYSTEM BARD #132075
Approvals — FDA: no, EMA: no, PMDA: no
Description: System B HeatSource fitted with a medium plugger at a temperature of 225 degrees C for 5 s on buccal and 5 s on lingual (Group 1)
Study: 12814227
Drug: System B
Normalized name: ACCESS PORT SYSTEM BARD #132075
Approvals — FDA: no, EMA: no, PMDA: no
Description: System B HeatSource fitted with a medium plugger at a temperature of 225 degrees C for 8 s on buccal and 8 s on lingual (Group 2)
Study: 28351689
Drug: Combined antigen/antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antigen/antibody and single antigen tests
Study: 27603149
Drug: Antiviral agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral agents along with Korean Red Ginseng powder capsules (1 gram per dose, 3 grams per day)
Study: 27603149
Drug: Antiviral agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral agents alone
Study: 19382496
Drug: EPs 7630,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPs 7630, a herbal drug preparation from the roots of Pelargonium sidoides, 60 drops three times daily for maximum 22 days
Study: 17688460
Drug: Adjunctive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapy combining lithium or valproate with olanzapine
Study: 17688460
Drug: Adjunctive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapy combining lithium or valproate with risperidone
Study: 17688460
Drug: Adjunctive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapy combining lithium or valproate with haloperidol
Study: 17688460
Drug: Adjunctive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapy combining lithium or valproate with quetiapine
Study: 17688460
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with agents like olanzapine, risperidone, haloperidol, or quetiapine
Study: 15481160
Drug: Topical IFN-alpha
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical IFN-alpha treatment for two weeks
Study: 7817528
Drug: Test diet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test diet (food fiber 55 g/day)
Study: 7817528
Drug: Routine diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine diet (food fiber 25 g/day)
Study: 2847348
Drug: LMWH-DHE (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH-DHE (1,500 U anti-Xa of LMWH + 0.5 mg DHE)
Study: 18214607
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5,000 IU)
Study: 24909188
Drug: Topical glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glycopyrrolate (2%)
Study: 16969659
Drug: Mechanical debridement
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical debridement with plastic curettes and antiseptic therapy (chlorhexidine digluconate 0.2%)
Study: 16304572
Drug: Allogeneic bone
Normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic bone marrow transplant (allo-BMT) after four blocks of intensive chemotherapy
Study: 16304572
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow transplant (A-BMT) after four blocks of intensive chemotherapy
Study: 16304572
Drug: Four blocks
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four blocks of treatment
Study: 16304572
Drug: Five blocks
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five blocks of treatment
Study: 16304572
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course of triple intrathecal chemotherapy for CNS-directed treatment
Study: 2718918
Drug: Estrogen-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-containing oral contraceptives (OCs)
Study: 2718918
Drug: Multivitamin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplementation (1700 micrograms vitamin A per capsule)
Study: 2718918
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A supplement (68,000 micrograms)
Study: 822857
Drug: Imipramine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (3 X 50 mg/day) + Thyrotrophin releasing hormone (TRH) (2 X 40 mg/day)
Study: 822857
Drug: Imipramine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (3 X 50 mg/day) + Placebo
Study: 26703981
Drug: Regular coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular coffee (450 mg/d caffeine content)
Study: 26703981
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (12 mg/d caffeine content)
Study: 21523716
Drug: Docetaxel (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (35 mg/m² on days 1 and 8) plus S-1 (35 mg/m² each twice daily on days 1-14)
Study: 21523716
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus cisplatin (35 mg/m² each on days 1 and 8)
Study: 16792583
Drug: drugs +
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: drugs + SLIT
Study: 3209626
Drug: Dispersible tablets
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible tablets of levodopa-benserazide
Study: 3209626
Drug: Standard capsule
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard capsule of levodopa-benserazide
Study: 28618234
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera 3% ointment, 1 g twice daily for 4 weeks
Study: 28618234
Drug: Placebo ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment, 1 g twice daily for 4 weeks
Study: 25141922
Drug: Ketamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (100 ng/ml)
Study: 23269816
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) emulsion, 0.2 g/kg, 3 infusions before and after surgery
Study: 21194588
Drug: Enzymatic cleanser
Normalized name: soft lens enzymatic cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzymatic cleanser solution (Polident 3 Minutes)
Study: 21194588
Drug: Cleanser solution
Normalized name: ACUICYN Eyelid & Eyelash Cleanser Solution
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cleanser solution (Corega Tabs)
Study: 21194588
Drug: 0.5% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% sodium hypochlorite (NaOCl) solution
Study: 18300086
Drug: Home-based computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based computer vergence/accommodative therapy and pencil push-ups
Study: 18300086
Drug: Office-based vergence/accommodative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based vergence/accommodative therapy with home reinforcement
Study: 19319008
Drug: Office-based placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based placebo therapy
Study: 3301517
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide dinitrate
Study: 9218088
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg isosorbide dinitrate
Study: 1382879
Drug: 1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg‐1 meperidine (Group 1, n = 30)
Study: 1382879
Drug: 1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg‐1 meperidine plus 0.5 mg.kg‐1 prilocaine (Group 2, n = 30)
Study: 1382879
Drug: 1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg‐1 meperidine plus 0.5 mg.kg‐1 prilocaine (Group 2)
Study: 2856710
Drug: Clonidine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.25 mg once daily)
Study: 2856710
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg twice daily) + Clonidine (0.25 mg once daily)
Study: 30888598
Drug: EGFR Tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EGFR Tyrosine Kinase Inhibitors (TKIs)
Study: 30888598
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with EGFR TKIs followed by Crizotinib
Study: 27537762
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg oral clonidine followed by 0.2 mg/d transdermal clonidine patch
Study: 12071024
Drug: Chemotherapy (preoperative,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (preoperative, postoperative, and pre- and postoperative)
Study: 10416139
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion sonography (SIS)
Study: 9219702
Drug: Preoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiotherapy (radiotherapy: 18.5 Gy in five fractions of 3.7 Gy each; cisplatin: 80 mg/m² body surface area administered 0 to 2 days before radiotherapy)
Study: 8388950
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 gm single dose)
Study: 28414043
Drug: Oral methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methotrexate, 25 mg weekly
Study: 28414043
Drug: Oral mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mycophenolate mofetil, 1 g twice daily
Study: 26590962
Drug: Intradiscal methylene
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal methylene blue injection (IMBI)
Study: 23159208
Drug: CCTA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCTA with 30 mL of contrast media (CM) following 5 mL of CM at timing bolus
Study: 23159208
Drug: CCTA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCTA with 50 mL of CM following 10 mL of CM at timing bolus
Study: 23159208
Drug: CT number-controlling
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT number-controlling system using the simple equation for CCTA following 5 mL of CM at timing bolus
Study: 21437603
Drug: Tyrosine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine (150 mg kg body mass(‐1))
Study: 21437603
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mL flavoured sugar‐free drink)
Study: 18458357
Drug: Caffeine 800
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 800 mg
Study: 12480560
Drug: Lactitol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactitol (60 g/day)
Study: 9196611
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (hGH) therapy
Study: 25512434
Drug: Intracoronary sodium
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary sodium nitrite (10 mL, 1.8 μmol)
Study: 25512434
Drug: Intracoronary sodium
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary sodium nitrite (10 mL, 1.8 μmol) in a subgroup of 66 patients with thrombolysis in myocardial infarction ≤1 flow
Study: 14647214
Drug: Hydrothermally treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrothermally treated barley porridge (28 mg P as InsP(3)-InsP(6))
Study: 14647214
Drug: Control porridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control porridge (111 mg P as InsP(3)-InsP(6))
Study: 14647214
Drug: Breakfast cereals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast cereals of malted barley (70 mg P as InsP(3)-InsP(6))
Study: 14647214
Drug: Flakes of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flakes of barley (108 mg P as InsP(3)-InsP(6), no phytase activity)
Study: 4091239
Drug: Etomidate (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (loading dose of 1 mg/kg b.w. within 15 minutes followed by continuous infusion of 1 mg/kg b.w./h until the end of ECC)
Study: 27348231
Drug: Aflibercept (Eylea®),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (Eylea®), a loading dose of three monthly injections (2 mg/0.05 ml) every 4 weeks for the first 3 months, followed by intravitreal injections every 2 months
Study: 24807339
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (400 micrograms every 3 hours after 800 micrograms vaginal loading dose)